The study of the safety and effect of high dose allopurinol in patients with severe heart failure
Phase 1
- Conditions
- Heart failure.
- Registration Number
- IRCT2015112125171N1
- Lead Sponsor
- Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Age of 18-80 years old; severe left ventricle systolic dysfunction (Ejection fraction of less than 35%) on optimal medical treatment for at least one month with New York heart association functional class of II-III; having informed written consent.
Exclusion criteria: Below the age of 18 and above the age of 80 years old; glomerular filtration rate of less than 60ml/min; serum creatinine level of more than 3mg/dl; severe hepatic failure; use of azathioprin; use of 6mercaptopurin; use of warfarin; known history of sensitivity to allopurinol.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ProBNP. Timepoint: 3 month. Method of measurement: Laboratory kit.;6 minute walk test. Timepoint: 3 month. Method of measurement: Rehabilitation department of the center.;Strain echocardiography. Timepoint: 3 month. Method of measurement: Vivid 6s echocardiography system.;Quality of life of the patients. Timepoint: 3 month. Method of measurement: IHF-QoL.
- Secondary Outcome Measures
Name Time Method Skin rash. Timepoint: during the 3 months. Method of measurement: Medical history and physical exam.;Gastrointestinal compliations. Timepoint: during the 3 months. Method of measurement: Medical history and physical exam.